Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
AssigneePharmacia Corporation
InventorsJohn P McKearn, Jaime L Masferrer, Luka Milas
Life of this patent
Estimating the term…
Abstract
The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of radiation therapy and a cyclooxygenase-2 inhibitor.
Claims23
A method for treating a neoplasia in a subject in need of such treatment wherein the method comprises treating the subject with an amount of radiation and a radiation-potentiating amount of a COX-2 inhibiting compound selected from the group consisting of celecoxib and 4-[5-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide wherein:
- the amount of radiation and the amount of the COX-2 inhibiting compound together comprise a neoplasia-treating-effective amount of the COX-2 inhibiting compound and the radiation;
- and
- the neoplasia is sensitive to such treatment.
A method for treating a neoplasia in a subject in need of such treatment wherein the method comprises treating the subject with an amount of radiation and a radiation-potentiating amount of a COX-2 inhibiting compound selected from the group consisting of celecoxib and 4-[5-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide wherein:
- the amount of radiation and the amount of the COX-2 inhibiting compound together comprise a neoplasia-treating-effective amount of the COX-2 inhibiting compound and the radiation;
- the amount of the COX-2 inhibiting compound is at least about 6 mg/kg of body weight per day;
- and
- the neoplasia is sensitive to such treatment.
A method for treating a neoplasia in a subject in need of such treatment wherein the method comprises treating the subject with an amount of radiation and a radiation-potentiating amount of a COX-2 inhibiting compound selected from the group consisting of celecoxib and 4-[5-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide wherein:
- the amount of radiation and the amount of the COX-2 inhibiting compound together comprise a neoplasia-treating-effective amount of the COX-2 inhibiting compound and the radiation;
- the amount of the COX-2 inhibiting compound is in the range of about 0.1 mg to about 10,000 mg per day;
- and
- the neoplasia is sensitive to such treatment.
The method of claim 21 wherein the amount of the COX-2 inhibiting compound is in the range of about 1 mg to about 1,000 mg per day.
The method of claim 22 wherein the COX-2 inhibiting compound is celecoxib.
Dependencies are inferred from the claim text.